IL325919A - שיטות אימונותרפיה עבור חולים אשר הגידולים שלהם נושאים מעמסת מוטצית גן נוסע גבוהה - Google Patents

שיטות אימונותרפיה עבור חולים אשר הגידולים שלהם נושאים מעמסת מוטצית גן נוסע גבוהה

Info

Publication number
IL325919A
IL325919A IL325919A IL32591926A IL325919A IL 325919 A IL325919 A IL 325919A IL 325919 A IL325919 A IL 325919A IL 32591926 A IL32591926 A IL 32591926A IL 325919 A IL325919 A IL 325919A
Authority
IL
Israel
Prior art keywords
gene mutation
patients whose
whose tumors
mutation burden
immunotherapy methods
Prior art date
Application number
IL325919A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL325919A publication Critical patent/IL325919A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/519—Detection characterised by immobilisation to a surface characterised by the capture moiety being a single stranded oligonucleotide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
IL325919A 2017-09-20 2018-09-19 שיטות אימונותרפיה עבור חולים אשר הגידולים שלהם נושאים מעמסת מוטצית גן נוסע גבוהה IL325919A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762560955P 2017-09-20 2017-09-20
PCT/US2018/051755 WO2019060418A1 (en) 2017-09-20 2018-09-19 IMMUNOTHERAPY METHODS FOR PATIENTS WITH TUMORS TRANSPORTING HIGH PASSENGER GENE MUTATION CHARGE

Publications (1)

Publication Number Publication Date
IL325919A true IL325919A (he) 2026-03-01

Family

ID=63794693

Family Applications (2)

Application Number Title Priority Date Filing Date
IL325919A IL325919A (he) 2017-09-20 2018-09-19 שיטות אימונותרפיה עבור חולים אשר הגידולים שלהם נושאים מעמסת מוטצית גן נוסע גבוהה
IL273263A IL273263B1 (he) 2017-09-20 2018-09-19 שיטות אימונותרפיה עבור חולים אשר הגידולים שלהם נושאים מעמסת מוטצית גן נוסע גבוהה

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL273263A IL273263B1 (he) 2017-09-20 2018-09-19 שיטות אימונותרפיה עבור חולים אשר הגידולים שלהם נושאים מעמסת מוטצית גן נוסע גבוהה

Country Status (15)

Country Link
US (3) US11640848B2 (he)
EP (2) EP3684955A1 (he)
JP (4) JP2020536051A (he)
KR (4) KR20200086371A (he)
CN (3) CN116850284A (he)
AU (3) AU2018336785B2 (he)
CA (1) CA3075927A1 (he)
IL (2) IL325919A (he)
MA (1) MA50271A (he)
MX (1) MX2020003204A (he)
RU (1) RU2020113600A (he)
SG (1) SG11202002282TA (he)
UA (1) UA128674C2 (he)
WO (1) WO2019060418A1 (he)
ZA (2) ZA202306801B (he)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EA201991673A1 (ru) * 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
AU2018336785B2 (en) * 2017-09-20 2022-07-14 Regeneron Pharmaceuticals, Inc. Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
MX2021012335A (es) * 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
CN110517726B (zh) * 2019-07-15 2023-07-04 西安电子科技大学 一种基于高通量测序数据的微生物成分及浓度检测方法
KR102164432B1 (ko) * 2019-09-18 2020-10-13 한국과학기술원 Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
EP4133109A4 (en) * 2020-04-10 2024-06-26 The Jackson Laboratory SYSTEMS AND METHODS FOR GROUPING AND VISUALIZING GENE VARIANTS
CN115552036A (zh) * 2020-05-12 2022-12-30 阿斯利康(瑞典)有限公司 用于预测复发性/转移性头颈部鳞状细胞癌的总生存期的生物标志物
CN111653312B (zh) * 2020-05-28 2021-04-16 上海宝藤生物医药科技股份有限公司 一种利用基因组数据探究疾病亚型亲缘性的方法
US11862315B2 (en) 2020-12-16 2024-01-02 Express Scripts Strategic Development, Inc. System and method for natural language processing
US11776672B1 (en) 2020-12-16 2023-10-03 Express Scripts Strategic Development, Inc. System and method for dynamically scoring data objects
US11423067B1 (en) 2020-12-16 2022-08-23 Express Scripts Strategic Development, Inc. System and method for identifying data object combinations
US20240254230A1 (en) * 2021-03-19 2024-08-01 Shanghai Junshi Biosciences Co., Ltd. Method of treating urothelial carcinoma
CN113106158A (zh) * 2021-06-16 2021-07-13 至本医疗科技（上海）有限公司 Csmd家族基因预测晚期肺腺癌免疫治疗疗效
CN116912160A (zh) * 2022-04-19 2023-10-20 佳能医疗系统株式会社 医用图像处理装置、变化度计算方法及非易失性存储介质
EP4608995A1 (en) * 2022-10-24 2025-09-03 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605A (en) 1850-08-27 Method
US238A (en) 1837-06-15 Capstan
US4863849A (en) 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US4971903A (en) 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
FR2703052B1 (fr) 1993-03-26 1995-06-02 Pasteur Institut Nouvelle méthode de séquençage d'acides nucléiques.
US6401267B1 (en) 1993-09-27 2002-06-11 Radoje Drmanac Methods and compositions for efficient nucleic acid sequencing
US5552278A (en) 1994-04-04 1996-09-03 Spectragen, Inc. DNA sequencing by stepwise ligation and cleavage
US5763594A (en) 1994-09-02 1998-06-09 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
EP0745686A1 (en) 1995-06-01 1996-12-04 Roche Diagnostics GmbH The use of DNA polymerase 3'-intrinsic editing activity
US6090549A (en) 1996-01-16 2000-07-18 University Of Chicago Use of continuous/contiguous stacking hybridization as a diagnostic tool
CZ293215B6 (cs) 1996-08-06 2004-03-17 F. Hoffmann-La Roche Ag Rekombinantní tepelně stálá DNA polymeráza, způsob její přípravy a prostředek, který ji obsahuje
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
EP1190100B1 (en) 1999-05-20 2012-07-25 Illumina, Inc. Combinatorial decoding of random nucleic acid arrays
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2003510063A (ja) 1999-09-30 2003-03-18 ニュー・イングランド・バイオラブズ・インコーポレイティッド 古細菌のｄｎａポリメラーゼによる修飾ヌクレオチドの取り込み及びそれに関する方法
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2001296645A1 (en) 2000-10-06 2002-04-15 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding dna and rna
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
WO2004018497A2 (en) 2002-08-23 2004-03-04 Solexa Limited Modified nucleotides for polynucleotide sequencing
CA2513899C (en) 2003-01-29 2013-03-26 454 Corporation Methods of amplifying and sequencing nucleic acids
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
GB0321306D0 (en) 2003-09-11 2003-10-15 Solexa Ltd Modified polymerases for improved incorporation of nucleotide analogues
US7754429B2 (en) 2006-10-06 2010-07-13 Illumina Cambridge Limited Method for pair-wise sequencing a plurity of target polynucleotides
US8951940B2 (en) 2010-04-01 2015-02-10 Illumina, Inc. Solid-phase clonal amplification and related methods
EP3090066A4 (en) 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
KR20230030022A (ko) * 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
EP3147664A1 (en) * 2015-09-22 2017-03-29 Institut Gustave Roussy A scoring method for predicting the efficiency of a treatment with anti-pd-1 and/or anti-pd-l1 monoclonal antibodies
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
LT3394103T (lt) 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
CN114959918A (zh) * 2016-02-29 2022-08-30 基础医疗股份有限公司 用于评估肿瘤突变负荷的方法和系统
CA3015913A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
CN106977602B (zh) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
AU2018336785B2 (en) * 2017-09-20 2022-07-14 Regeneron Pharmaceuticals, Inc. Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

Also Published As

Publication number Publication date
US11640848B2 (en) 2023-05-02
EP4589014A3 (en) 2025-10-15
EP3684955A1 (en) 2020-07-29
ZA202401565B (en) 2024-11-27
EP4589014A2 (en) 2025-07-23
SG11202002282TA (en) 2020-04-29
KR20200059243A (ko) 2020-05-28
KR20200086371A (ko) 2020-07-16
IL273263A (he) 2020-04-30
KR102667593B1 (ko) 2024-05-22
MA50271A (fr) 2020-07-29
AU2022209279B2 (en) 2024-09-12
AU2018336785A1 (en) 2020-04-23
JP2020536051A (ja) 2020-12-10
AU2024205632B2 (en) 2026-03-12
RU2020113600A3 (he) 2021-10-20
US20250218540A1 (en) 2025-07-03
CA3075927A1 (en) 2019-03-28
WO2019060418A1 (en) 2019-03-28
JP2024099700A (ja) 2024-07-25
AU2022209279A1 (en) 2022-09-15
CN111133115A (zh) 2020-05-08
JP7753432B2 (ja) 2025-10-14
JP7525565B2 (ja) 2024-07-30
US20230268028A1 (en) 2023-08-24
NZ763327A (en) 2023-09-29
AU2018336785B2 (en) 2022-07-14
AU2024205632A1 (en) 2024-08-29
RU2020113600A (ru) 2021-10-20
IL273263B1 (he) 2026-02-01
US12230364B2 (en) 2025-02-18
KR20220051434A (ko) 2022-04-26
CN116850284A (zh) 2023-10-10
MX2020003204A (es) 2020-07-20
CN116850285A (zh) 2023-10-10
JP2022183175A (ja) 2022-12-08
US20190087538A1 (en) 2019-03-21
JP2026001138A (ja) 2026-01-06
KR20240074006A (ko) 2024-05-27
ZA202306801B (en) 2024-01-31
UA128674C2 (uk) 2024-09-25

Similar Documents

Publication Publication Date Title
IL273263A (he) שיטות אימונותרפיה עבור חולים אשר הגידולים שלהם נושאים מעמסת מוטצית גן נוסע גבוהה
AU201616817S (en) Cushion for patient interface
AU201616820S (en) Cushion for patient interface
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
SG10201913631TA (en) Rna for cancer therapy
PL4101418T3 (pl) Układ wytwarzania aparatu ortodontycznego
GB2549378B (en) Lift assembly for patient support apparatus
SG11201700944RA (en) Microrna biomarker for the diagnosis of gastric cancer
IL247508A0 (he) שיטה להכנת חלבוני פלזמה אנושיים
PL3553087T3 (pl) Terapia celowana nowotworu złośliwego płuc
SG11202000650YA (en) Factor viii (fviii) gene therapy methods
GB2551892B (en) Cancer treatment - proton tomography apparatus
ZA201700160B (en) Method for selecting personalized tri-therapy for cancer treatment
SG11201701051RA (en) A method for prognosis of ovarian cancer, patient's stratification
EP3201360A4 (en) Methods for assessing risk of developing breast cancer
PL3894407T3 (pl) Sposób wytwarzania apiksabanu
EP3221866A4 (en) Apparatus for preparing medical radioisotopes
EP3165619A4 (en) Method for smelting nickel oxide ore
GB201707212D0 (en) Gene therapy for ciliopathies
GB201908591D0 (en) Methods for cancer diagnosis
SG11201609858UA (en) Apparatus for retina phototherapy
EP3180011A4 (en) Immunotherapy for the treatment of cancer
EP3203951A4 (en) Template for bilateral symmetric stimulator fixation/implantation
IL293030B2 (he) גירויים שגורמים להיפראקטיביות של תאים דנדריטים מקומיים לאימונותרפיה של סרטן
SG11202106249QA (en) Methods for improved immunotherapy